Ciprofibrate
Chemical compound
- C10AB08 (WHO)
- (RS)-2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-
methylpropanoic acid
- 52214-84-3
- 2763
- 3438
- 2661
Y
- F8252JGO9S
- D03521 Y
- CHEBI:50867 Y
- ChEMBL557555 Y
- DTXSID8020331
- Interactive image
- ClC2(Cl)CC2c1ccc(OC(C(=O)O)(C)C)cc1
InChI
- InChI=1S/C13H14Cl2O3/c1-12(2,11(16)17)18-9-5-3-8(4-6-9)10-7-13(10,14)15/h3-6,10H,7H2,1-2H3,(H,16,17)Y
- Key:KPSRODZRAIWAKH-UHFFFAOYSA-NY
Ciprofibrate is a fibrate that was developed as a lipid-lowering agent.
It was patented in 1972 and approved for medical use in 1985.[1]
References
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 474. ISBN 9783527607495.
- v
- t
- e
Lipid-lowering agents (C10)
| Cholesterol absorption inhibitors, NPC1L1 | |
|---|---|
| Bile acid sequestrants/resins (LDL) |
| Statins (HMG-CoA reductase, LDL) | |
|---|---|
| Niacin and derivatives (HDL and LDL) | |
| MTTP inhibitors (VLDL) | |
| ATP citrate lyase inhibitors (LDL) | |
| Thyromimetics (VLDL) |
| PPAR agonists (LDL) |
| ||||
|---|---|---|---|---|---|
| CETP inhibitors (HDL) | |||||
| PCSK9 inhibitors (LDL) | |||||
| ANGPTL3 inhibitors (LDL/HDL) |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
